Design, synthesis, and biological evaluation of novel benzylidene-N-(3,4 dichlorophenyl) hydrazine-1-carbothioamide derivatives as new acetylcholinesterase inhibitors

Abstract

Alzheimer’s disease (AD) is a continuous worsening condition of the nervous system in which brain cells degenerate over time, leading to impairments in memory and thinking, and it is linked to a decrease in acetylcholine concentrations in the brain, a neurotransmitter crucial for memory and learning. Targeting acetylcholinesterase (AChE) inhibition remains a fundamental treatment strategy. The goal of this study was to design and synthesize a series of new benzylidene-N-(3,4-dichlorophenyl)hydrazine-1-carbothioamide derivatives 3a-3g as potential acetylcholinesterase (AChE) inhibitors for Alzheimer’s disease therapy. By integrating synthesis, biological evaluation, docking analysis, and pharmacokinetic predictions, the study presents a complete strategy that not only discovers effective inhibitors but also confirms their drug-like features. This multi-faceted strategy strengthens the reliability of the findings and highlights compound 3g as a robust lead candidate. The synthesis of derivatives was validated by employing 1HNMR, 13CNMR and HRMS spectroscopy. Biological assays demonstrated AChE inhibitory properties of the synthesized molecules, with compound 3g showing the most potent inhibitor activity, exhibiting IC₅₀ values of 0.055±0.002 µM for AChE and no activity toward BChE enzyme. Docking studies supported these results by demonstrating favorable binding conformation and stability, while pharmacokinetic and drug-likeness analyses further established compound 3g as a promising lead candidate for AD therapy.

Keywords

• Acetylcholinesterase inhibitors
• Alzheimer’s disease
• hydrazine carbothioamide
• molecular docking study
• pharmacokinetic study

Project Number

2204S034 and 2209S149

References

1. DeTure, M. A., & Dickson, D. W. (2019). The neuropathological diagnosis of Alzheimer’s disease. Molecular Neurodegeneration, 14(1), 32. https://doi.org/10.1186/s13024-019-0333-5
2. Korabecny, J., Zemek, F., Soukup, O., Spilovska, K., Musilek, K., Jun, D., Nepovimova, E., & Kuca, K. (2014). Pharmacotherapy of Alzheimer’s Disease: Current State and Future Perspectives. In Drug Design and Discovery in Alzheimer’s Disease (pp. 3–39). Elsevier. https://doi.org/10.1016/B978-0-12-803959-5.50001-5
3. World Alzheimer Report 2021: Journey through the diagnosis of dementia. (n.d.).
4. Haji Ali, S., Osmaniye, D., Sağlık, B. N., Levent, S., Özkay, Y., & Kaplancıklı, Z. A. (2022). Design, Synthesis, and Evaluation of Novel 2H-Benzo[b][1,4]thiazin-3(4H)-one Derivatives as New Acetylcholinesterase Inhibitors. Molecules, 27(7), 2121. https://doi.org/10.3390/molecules27072121
5. Budimir, A. (2011). Metal ions, Alzheimer’s disease and chelation therapy. Acta Pharmaceutica (Zagreb, Croatia), 61(1), 1–14. https://doi.org/10.2478/v10007-011-0006-6
6. Grand, J. H., Caspar, S., & MacDonald, S. W. (2011). Clinical features and multidisciplinary approaches to dementia care. Journal of Multidisciplinary Healthcare, 4, 125–147. https://doi.org/10.2147/JMDH.S17773
7. Godyń, J., Jończyk, J., Panek, D., & Malawska, B. (2016). Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacological Reports: PR, 68(1), 127–138. https://doi.org/10.1016/j.pharep.2015.07.006
8. Connelly, P. J., Prentice, N. P., & Fowler, K. G. (2005). Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer’s disease. Journal of Neurology, Neurosurgery, and Psychiatry, 76(3), 320–324. https://doi.org/10.1136/jnnp.2004.043539

9. 2021 Alzheimer’s disease facts and figures. (2021). Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 17(3), 327–406. https://doi.org/10.1002/alz.12328
10. Breijyeh, Z., & Karaman, R. (2020). Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules, 25(24), 5789. https://doi.org/10.3390/molecules25245789
11. Courtney, C., Farrell, D., Gray, R., Hills, R., Lynch, L., Sellwood, E., Edwards, S., Hardyman, W., Raftery, J., Crome, P., Lendon, C., Shaw, H., Bentham, P., & AD2000 Collaborative Group. (2004). Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): Randomised double-blind trial. Lancet (London, England), 363(9427), 2105–2115. https://doi.org/10.1016/S0140-6736(04)16499-4
12. Smith, D. G., Cappai, R., & Barnham, K. J. (2007). The redox chemistry of the Alzheimer’s disease amyloid beta peptide. Biochimica Et Biophysica Acta, 1768(8), 1976–1990. https://doi.org/10.1016/j.bbamem.2007.02.002
13. Chen, Y.-G. (2018). Research Progress in the Pathogenesis of Alzheimer’s Disease. Chinese Medical Journal, 131(13), 1618–1624. https://doi.org/10.4103/0366-6999.235112
14. Samadi, A., Marco-Contelles, J., Soriano, E., Álvarez-Pérez, M., Chioua, M., Romero, A., González-Lafuente, L., Gandía, L., Roda, J. M., López, M. G., Villarroya, M., García, A. G., & Ríos, C. de los. (2010). Multipotent drugs with cholinergic and neuroprotective properties for the treatment of Alzheimer and neuronal vascular diseases. I. Synthesis, biological assessment, and molecular modeling of simple and readily available 2-aminopyridine-, and 2-chloropyridine-3,5-dicarbonitriles. Bioorganic & Medicinal Chemistry, 18(16), 5861–5872. https://doi.org/10.1016/j.bmc.2010.06.095
15. Holmes, C. (2013). Review: Systemic inflammation and Alzheimer’s disease. Neuropathology and Applied Neurobiology, 39(1), 51–68. https://doi.org/10.1111/j.1365-2990.2012.01307.x
16. Oliver, D. M. A., & Reddy, P. H. (2019). Small molecules as therapeutic drugs for Alzheimer’s disease. Molecular and Cellular Neuroscience, 96, 47–62. https://doi.org/10.1016/j.mcn.2019.03.001
17. Su, T. Z., Lunney, E., Campbell, G., & Oxender, D. L. (1995). Transport of gabapentin, a gamma-amino acid drug, by system l alpha-amino acid transporters: A comparative study in astrocytes, synaptosomes, and CHO cells. Journal of Neurochemistry, 64(5), 2125–2131.
18. Henstridge, C. M., Pickett, E., & Spires-Jones, T. L. (2016). Synaptic pathology: A shared mechanism in neurological disease. Ageing Research Reviews, 28, 72–84. https://doi.org/10.1016/j.arr.2016.04.005
19. García-Ayllón, M.-S., Silveyra, M.-X., & Sáez-Valero, J. (2008). Association between acetylcholinesterase and beta-amyloid peptide in Alzheimer’s cerebrospinal fluid. Chemico-Biological Interactions, 175(1–3), 209–215. https://doi.org/10.1016/j.cbi.2008.04.047
20. Dumas, J. A., & Newhouse, P. A. (2011). The cholinergic hypothesis of cognitive aging revisited again: Cholinergic functional compensation. Pharmacology, Biochemistry, and Behavior, 99(2), 254–261. https://doi.org/10.1016/j.pbb.2011.02.022
21. Bartus, R. T. (2000). On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Experimental Neurology, 163(2), 495–529. https://doi.org/10.1006/exnr.2000.7397
22. Atri, A., Frölich, L., Ballard, C., Tariot, P. N., Molinuevo, J. L., Boneva, N., Windfeld, K., Raket, L. L., & Cummings, J. L. (2018). Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials. JAMA, 319(2), 130–142. https://doi.org/10.1001/jama.2017.20373
23. Doody, R. S., Dunn, J. K., Clark, C. M., Farlow, M., Foster, N. L., Liao, T., Gonzales, N., Lai, E., & Massman, P. (2001). Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders, 12(4), 295–300. https://doi.org/10.1159/000051272
24. Lahiri, D. K., Farlow, M. R., Greig, N. H., & Sambamurti, K. (2002). Current drug targets for Alzheimer’s disease treatment. Drug Development Research, 56(3), 267–281. https://doi.org/10.1002/ddr.10081
25. Craig, L. A., Hong, N. S., & McDonald, R. J. (2011). Revisiting the cholinergic hypothesis in the development of Alzheimer’s disease. Neuroscience & Biobehavioral Reviews, 35(6), 1397–1409. https://doi.org/10.1016/j.neubiorev.2011.03.001
26. AL-Zahrani, A. A., Awwad, N. S., Ibrahium, H. A., Hayat, S., Ullah, H., Javed, Z., Rahim, F., Khan, M. S., Zada, H., Rab, A., Raza, K., & Wadood, A. (2023). Thiosemicarbazone derivatives as potential inhibitors of acetylcholinesterase, butyrylcholinesterase and their molecular docking studies. Chemical Data Collections, 45, 101014. https://doi.org/10.1016/j.cdc.2023.101014
27. Rahim, F., Ullah, H., Taha, M., Hussain, R., Iqbal, R., Iqbal, N., Khan, S., Shah, S. A., Shah, Albalawi, M., Abdelaziz, M., Fatema, S., Alatawi, Alasmari, A., Sakran, M., Zidan, N., Jafri, I., & Khan, K. (2022). Synthesis of New Triazole-Based Thiosemicarbazone Derivatives as Anti-Alzheimer’s Disease Candidates: Evidence-Based In Vitro Study. Molecules, 28, 21. https://doi.org/10.3390/molecules28010021
28. Haji Ali, S., Osmaniye, D., & Asım Kaplancıklı, Z. (2025). Synthesis and biological evaluation of novel hydrazone derivatives for the treatment of Alzheimer’s disease. RSC Advances, 15(53), 45729–45743. https://doi.org/10.1039/D5RA05755H
29. Ellman, G. L., Courtney, K. D., Andres, V., & Featherstone, R. M. (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochemical Pharmacology, 7(2), 88–95. https://doi.org/10.1016/0006-2952(61)90145-9
30. Bank, R. P. D. (n.d.). RCSB PDB - 4EY7: Crystal Structure of Recombinant Human Acetylcholinesterase in Complex with Donepezil. Retrieved March 21, 2025, from https://www.rcsb.org/structure/4EY7
31. Schrödinger Release 2020-3, Maestro, Schrödinger, LLC, New York, NY, USA, 2020.
32. Schrödinger Release. 2020-1: LigPrep 2020, Schrödinger, LLC, New York, NY, USA, 2020.
33. Schrödinger Release 2020-3, Glide, Schrödinger, LLC, New York, NY, USA, 2020.
34. Pires, D. E. V., Blundell, T. L., & Ascher, D. B. (2015). pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. Journal of Medicinal Chemistry, 58(9), 4066–4072. https://doi.org/10.1021/acs.jmedchem.5b00104
35. SwissADME.. Retrieved May 11, 2023, from http://www.swissadme.ch/
36. Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7(1), 42717. https://doi.org/10.1038/srep42717
37. Ali, S. H., Osmaniye, D., & Kaplancıklı, Z. A. (2025). Synthesis and biological evaluation of novel hydrazone derivatives for the treatment of Alzheimer’s disease. RSC Advances, 15(53), 45729–45743. https://doi.org/10.1039/D5RA05755H
38. Tok, F., Koçyiğit-Kaymakçıoğlu, B., Sağlık, B. N., Levent, S., Özkay, Y., & Kaplancıklı, Z. A. (2019). Synthesis and biological evaluation of new pyrazolone Schiff bases as monoamine oxidase and cholinesterase inhibitors. Bioorganic Chemistry, 84, 41–50. https://doi.org/10.1016/j.bioorg.2018.11.016
39. Acar Cevik, U., Saglik, B. N., Levent, S., Osmaniye, D., Kaya Cavuşoglu, B., Ozkay, Y., & Kaplancikli, Z. A. (2019). Synthesis and AChE-Inhibitory Activity of New Benzimidazole Derivatives. Molecules, 24(5), 861. https://doi.org/10.3390/molecules24050861
40. Osmaniye, D., Sağlık, B. N., Acar Çevik, U., Levent, S., Kaya Çavuşoğlu, B., Özkay, Y., Kaplancıklı, Z. A., & Turan, G. (2019). Synthesis and AChE Inhibitory Activity of Novel Thiazolylhydrazone Derivatives. Molecules, 24(13), 2392. https://doi.org/10.3390/molecules24132392
41. Sağlık, B. N., Ilgın, S., & Özkay, Y. (2016). Synthesis of new donepezil analogues and investigation of their effects on cholinesterase enzymes. European Journal of Medicinal Chemistry, 124, 1026–1040. https://doi.org/10.1016/j.ejmech.2016.10.042
42. Acar Çevi̇k, U., Levent, S., Sağlik, B., Özkay, Y., & Kaplancikli, Z. (2017). Synthesis of Novel 4-(Dimethylaminoalkyl) piperazine-1-carbodithioate Derivatives as Cholinesterase Inhibitors. LETTERS IN DRUG DESIGN & DISCOVERY, 14(5). https://doi.org/10.2174/1570180813666160923105636
43. Sağlık, B. N., Osmaniye, D., Acar Çevik, U., Levent, S., Kaya Çavuşoğlu, B., Özkay, Y., & Kaplancıklı, Z. A. (2020). Design, Synthesis, and Structure–Activity Relationships of Thiazole Analogs as Anticholinesterase Agents for Alzheimer’s Disease. Molecules, 25(18), 4312. https://doi.org/10.3390/molecules25184312